Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Creatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 14/20 | 0.36 |
| ▸ | CA2 | P00918 | 14/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatine SCHEMBL27189 | 0.98 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL10710660 | 0.98 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL2817384 | 0.98 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL4110519 | 0.98 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL15514026 | 0.98 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL4966668 | 0.98 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL28000876 | 0.98 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL21693688 | 0.96 | MVD (0.45) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL21693685 | 0.96 | MVD (0.41) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL21693673 | 0.96 | MVD (0.41) | MVDNOS3NOS1NOS2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279708-B2 | Amidino- and amino-rocaglates as novel translation inhibitors and anticancer agents | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2020252173-A1 | AMIDINO- AND AMINO-ROCAGLATES AS NOVEL TRANSLATION INHIBITORS AND ANTICANCER AGENTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392147-A1 | AMIDINO- AND AMINO-ROCAGLATES AS NOVEL TRANSLATION INHIBITORS AND ANTICANCER AGENTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392147-A1 | AMIDINO- AND AMINO-ROCAGLATES AS NOVEL TRANSLATION INHIBITORS AND ANTICANCER AGENTS | EIF2B3, EIF4EBP1, G3BP1 | MVD 1007/4885NOS3 2783/4885NOS1 3531/4885 |
| US-11279708-B2 | Amidino- and amino-rocaglates as novel translation inhibitors and anticancer agents | EIF2B3, EIF4EBP1, G3BP1 | MVD 1007/4885NOS3 2783/4885NOS1 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.